Effect of osmotic pressure on the production of retroviral vectors: Enhancement in vector stability.

scientific article published on June 2006

Effect of osmotic pressure on the production of retroviral vectors: Enhancement in vector stability. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1002/BIT.20847
P698PubMed publication ID16528756
P5875ResearchGate publication ID7249237

P50authorAna S. CoroadinhaQ37829098
Manuel J T CarrondoQ39062238
Paula Marques AlvesQ39849137
Ana Varela CoelhoQ44157990
P2093author name stringSilva AC
Pires E
P2860cites workA RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATIONQ25939000
Plat-E: an efficient and stable system for transient packaging of retrovirusesQ29614830
P433issue2
P304page(s)322-329
P577publication date2006-06-01
P1433published inBiotechnology and BioengineeringQ4915339
P1476titleEffect of osmotic pressure on the production of retroviral vectors: Enhancement in vector stability
P478volume94

Reverse relations

cites work (P2860)
Q39425985Adaptation of retrovirus producer cells to serum deprivation: Implications in lipid biosynthesis and vector production
Q39527949Down-regulation of CD81 tetraspanin in human cells producing retroviral-based particles: tailoring vector composition.
Q47550880Flexible pseudotyping of retrovirus using recombinase-mediated cassette exchange
Q39484103Fucose content of monoclonal antibodies can be controlled by culture medium osmolality for high antibody-dependent cellular cytotoxicity
Q35180417Genetic modification of human hematopoietic cells: preclinical optimization of oncoretroviral-mediated gene transfer for clinical trials
Q38857837Increased titer and reduced lactate accumulation in recombinant retrovirus production through the down-regulation of HIF1 and PDK.
Q38099382New developments in lentiviral vector design, production and purification
Q36095367Retroviral particles are effectively purified on an affinity matrix containing peptides selected by phage-display
Q33315244Retroviral vectors for clinical immunogene therapy are stable for up to 9 years
Q57097099Strategies for improved stability of Peste des Petits Ruminants Vaccine

Search more.